ANTONARELLI, GABRIELE
ANTONARELLI, GABRIELE
Universita' degli Studi di MILANO
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers
2023 P. Zagami, A. Comandone, M. Fiore, G. Giulio Baldi, G. Grignani, B. Vincenzi, A. Gronchi, G. Antonarelli, A. Boglione, E. Pennacchioli, G. Curigliano, F. Conforti, T.M. De Pas
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Harmonizing PD-L1 testing in metastatic triple negative breast cancer
2022 F. Giugliano, G. Antonarelli, P. Tarantino, J. Cortes, H.S. Rugo, G. Curigliano
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group
2022 G. Antonarelli, C. Corti, P.A. Zucali, M. Perrino, S. Manglaviti, G. Lo Russo, G.M. Varano, P. Salvini, G. Curigliano, C. Catania, F. Conforti, T. De Pas
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
2022 C. Corti, G. Antonarelli, F. Scotte, J.P. Spano, J. Barriere, J.M. Michot, F. Andre, G. Curigliano
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
2022 C. Corti, G. Antonarelli, C. Valenza, E. Nicolò, H. Rugo, J. Cortés, N. Harbeck, L.A. Carey, C. Criscitiello, G. Curigliano
Targeting brain metastases in breast cancer
2022 C. Corti, G. Antonarelli, C. Criscitiello, N.U. Lin, L.A. Carey, J. Cortes, P. Poortmans, G. Curigliano
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development
2022 P. Tarantino, G. Antonarelli, L. Ascione, G. Curigliano
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?
2022 G. Antonarelli, C. Valenza, E.L. Mayer, S. Loibl, G. Curigliano
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies
2021 G. Antonarelli, F. Giugliano, C. Corti, M. Repetto, P. Tarantino, G. Curigliano
Therapeutic Cancer Vaccines Revamping: Technology Advancements and Pitfalls
2021 G. Antonarelli, C. Corti, P. Tarantino, L. Ascione, J. Cortes, P. Romero, E.A. Mittendorf, M.L. Disis, G. Curigliano
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy
2021 L. Mazzarella, F. Giugliano, E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, E. Nicolo, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, C. Belli, C. Criscitiello, A. Esposito, M. Locatelli, I. Minchella, G. Curigliano
COVID-19 related risk in patients enrolled in early-phase clinical trials
2021 P. D'Amico, P. Trillo, S. Morganti, C. Corti, G. Vivanet, E. Crimini, L. Ascione, P. Tarantino, G. Antonarelli, M. Locatelli, A. Esposito, C. Belli, G. Curigliano
Systemic Treatment of Ductal Carcinoma In Situ of the Breast
2021 E. Crimini, C. Corti, M. Repetto, F. Giugliano, G. Antonarelli, P. Tarantino, P. Zagami, S. Morganti, E. Nicolo, J. Uliano, G. Curigliano
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials
2021 P. Trillo Aliaga, D. Trapani, J.L. Sandoval, E. Crimini, G. Antonarelli, G. Vivanet, S. Morganti, C. Corti, P. Tarantino, A. Friedlaender, C. Belli, I. Minchella, M. Locatelli, A. Esposito, C. Criscitiello, G. Curigliano